The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus

Abstract

Background Pharmacokinetic and efficacy data on dolutegravir in pregnant women living with human immunodeficiency virus (HIV) are still limited but needed to support its use as one of the preferred antiretroviral agents. Methods Within the multicenter Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) study, pregnant women living with HIV and using dolutegravir once daily (50 mg, with food) underwent 24-hour pharmacokinetic profiling in their third trimester and postpartum. Dolutegravir exposure in the third trimester was considered adequate if geometric mean unbound, pharmacologically active, minimal plasma concentrations (Cmin, unbound) and ≥90% of individual Cmin, unbound levels were >0.85 µg/L, the proposed 90% inhibitory concentration for unbound dolutegravir. Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) for comparison of total and unbound pharmacokinetic parameters in the third trimester and postpartum were calculated, including the metabolic ratio for dolutegravir-glucuronide. Safety and virological data were collected. Results Seventeen women (76% black) were enrolled (25 evaluable pharmacokinetic profiles; 15 in the third trimester, 10 in postpartum). In the third trimester, geometric mean (coefficient of variation, %) Cmin, unbound was 2.87 (87) µg/L and 93% of individual Cmin, unbound levels were >0.85 µg/L. The GMR (90% CI) in the third trimester vs postpartum was 0.86 (.68–1.10) for area under the curve (AUC0-24h), and for Cmax, 0.93 (.77–1.13). GMR (90% CI) for the trough concentrations was 0.71 (.49–1.02), based on total dolutegravir concentrations. Four serious adverse events were reported, unlikely related to dolutegravir. The HIV polymerase chain reaction test was negative in 14/17 infants (result unknown for 3 infants). Conclusions Pharmacokinetic changes for dolutegravir in late pregnancy are not clinically relevant and support the use of dolutegravir 50 mg once daily with food in pregnancy. Clinical Trials Registration NCT00825929.

Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling

“…Combined with the results from the sensitivity analysis on UGT1A1 induction (Fig. S4), this finding emphasizes that UGT1A1 induction may be lower than expected here and that changes in the fraction unbound are, at least for DTG, the main driver of increased total clearance which is consistent with recent findings in the literature [46]. The PK of RAL was generally well predicted in pregnant, non-laboring women (Fig.…”

Inhibition of matrix metalloproteinases by HIV-1 integrase strand transfer inhibitors

“…Clinical and pre-clinical studies showed high levels of transplacental transfer of INSTI drugs ( Schalkwijk et al, 2016 ; Mulligan et al, 2018 ; Mandelbrot et al, 2019 ; Waitt et al, 2019 ; Bollen et al, 2021 ; Bukkems et al, 2021 ). Studies of DTG have found high placental transfer of DTG from mother to fetus with median cord blood to maternal blood drug level ratios from 1.21 up to 1.29 ( Schalkwijk et al, 2016 ; Mulligan et al, 2018 ; Mandelbrot et al, 2019 ; Waitt et al, 2019 ; Bollen et al, 2021 ). Further, DTG was also found to accumulate in the fetus with noted prolonged elimination of drug from infants after birth ( Mulligan et al, 2018 ; Waitt et al, 2019 ).…”

Pharmacokinetics of Antiretroviral Agents in Pregnant Individuals Living With HIV: Current Status and Considerations for Study Design and Interpretation

“…For boosted ARVs, if the key mechanism of lower exposures during pregnancy is due to lower exposures of PK boosters (ritonavir or cobicistat), then a dose increase of the PK booster rather than a dose increase of the boosted ARV (eg, protease inhibitor) can potentially be considered to achieve the target concentration correlating with efficacy. 35 When recommending a dose increase during pregnancy, an overall risk-benefit assessment should be considered. In Bonafe et al, 36 pregnant individuals assigned to receive an increased dose of lopinavir/ritonavir had a higher rate of diarrhea as compared to those who were using lopinavir/ritonavir at the time of randomization and who were assigned to receive the conventional dose.…”